Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC Project
01 Julio 2004 - 8:31AM
PR Newswire (US)
Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for
the EUROVAC Project STRASBOURG, France, July 1
/PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Nouveau Marche:
FR0005175080) today announced that it manufactured clinical lots of
HIV vaccine candidates in the frame of EUROVAC (European Vaccine
Effort against HIV/AIDS), a European cluster of 21 laboratories,
funded since 2000 by the European Union under the 5th Framework
Programme. Partners of EUROVAC, the Karolinska Institutet and
Aventis Pasteur, recognizing Transgene's know-how in the field of
recombinant vaccines production, selected the company to produce
clinical lots of NYVAC-based vaccines carrying genes of HIV-1.
Production was completed in Transgene's manufacturing facility
located near Strasbourg, through adaptation of its own MVA
manufacturing process to the production of NYVAC-based products.
NYVAC and MVA are both attenuated strains of the vaccinia virus.
"We are very proud of the confidence put in us by the Karolinska
Institutet, EUROVAC and Aventis Pasteur for our manufacturing
capabilities of recombinant vaccines," stated Jean-Francois
Carmier, Chief Executive Officer of Transgene. "We believe
manufacturing contracts add value to our expertise, while
contributing to reducing our burn rate." About Transgene Transgene,
based in Strasbourg, France, is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines,
immunotherapy products, and delivery technologies for the treatment
of diseases for which there is no cure or adequate treatment at
present, with a focus on the treatment of cancer. Transgene has
five products in clinical development, two of which are in Phase II
clinical trials, two in Phase I/II and one that has completed Phase
I clinical trial. Transgene's proprietary vector technology
platform consists of adenovirus and poxvirus. This press release
contains forward-looking statements, including statements regarding
Transgene manufacturing capabilities. Statements that are not
historical facts are based on Transgene's current expectations,
beliefs, estimates, forecasts and assumptions, including
Transgene's expectations related to the reproducibility in humans
of the preclinical results, progress in the clinical trials and
Transgene's belief as to the potential to successfully manufacture
products for the effective treatment of illness. The statements
contained in this release are not guarantees of future performance
and involve certain risks, uncertainties and assumptions which are
difficult to predict. Accordingly, actual outcomes and results may
differ materially from what is expressed in those forward-looking
statements. Important factors which may affect Transgene's future
operating results include the following: Transgene's product
candidates may not demonstrate therapeutic efficacy after initial
promising results, Transgene may be unable to obtain regulatory
approval for its product candidates, Transgene may be unable to
conduct its clinical trials as quickly as it has predicted,
Transgene's clinical trials may not produce results sufficient to
justify further product development, Transgene may not have
sufficient resources to complete the research, manufacturing and
commercialization of any of its product candidates, competitors may
develop technologies or products superior to Transgene's
technologies or products, Transgene may not be able to successfully
enforce the intellectual property rights in all jurisdictions
relating to its product candidates and other important factors
described in Transgene's Annual Report on Form 20-F for the year
ended December 31, 2003 filed with the U.S. Securities and Exchange
Commission, including those factors described in the section
entitled "Risk Factors." DATASOURCE: Transgene CONTACT: Michel
Hubert, VP Business Development, Transgene, +33-3-88-27-91-12;
Michael Long, Cohn & Wolfe, +1-212-798-9775; Estelle
Guillot-Tantay, +33-1-53-70-74-93, or Laurence Heilbronn,
+33-1-53-70-74-64, both of Image 7, for Transgene
Copyright